Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC)

(2017) W. Gerritsen et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall survival (OS) analysis of a phase II study using a pox viral-based vaccine, PSA-TRICOM, in the treatment of metastatic, castrate-resistant prostate cancer (mCRPC): Implications for clinical trial design

(2017) R. A. Madan et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Statistics, 2008

(2008) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

(2008) Albana Cumashi et al.   CANCER LETTERS

Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

(2008) C. T. Garnett et al.   CLINICAL CANCER RESEARCH

Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant

(2008) R. J. Lechleider et al.   CLINICAL CANCER RESEARCH

Analysis of Overall Survival in Patients with Nonmetastatic Castration-Resistant Prostate Cancer Treated with Vaccine, Nilutamide, and Combination Therapy

(2008) R. A. Madan et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Sunitinib for the Therapy of Progressive Metastatic Castration-Refractory Prostate Cancer After Previous Docetaxel Chemotherapy

(2008) Guru Sonpavde et al.   Clinical Genitourinary Cancer

Sipuleucel-T: A Vaccine for Metastatic, Asymptomatic, Androgen-Independent Prostate Cancer

(2007) Punam H Patel et al.   ANNALS OF PHARMACOTHERAPY